论文部分内容阅读
实验选择发热期的流行性出血热(EHF)患者,随机分为试验组(23人),对照组(22人)。试验组除与对照组相同方法治疗外加服抗病毒合剂。结果试验组病例发热持续时间平均缩短1.8天;蛋白尿转阴提前1.6天;血液尿素氮增高持续时间减少2.3天;血小饭恢复正常平均早1.6天。越低血压期、越少尿期、越低血压和少尿两期试验组和对照组的比率分别为82.6％(19/23)和54.5％(12/22);78.3％(13/23)和50％(11/22);65.2％(15/23)和40.9％(9/22)。观察结果表明:加服抗病毒合剂对治疗流行性出血热有明显的临床效果。
Patients with epidemic hemorrhagic fever (EHF) were randomly divided into experimental group (23) and control group (22). In addition to the experimental group with the same method as the control group plus an anti-virus mixture. Results In the experimental group, the duration of febrile illness was shortened by 1.8 days on average; the proteinuria turned negative 1.6 days earlier; the duration of blood urea nitrogen increased by 2.3 days; and the blood meal returned to normal as early as 1.6 days. The rates of lower hypotension, oliguria, lower blood pressure and oliguria were 82.6% (19/23) and 54.5% (12/22) respectively in the two experimental groups and 78.3% (13/23) And 50% (11/22); 65.2% (15/23) and 40.9% (9/22) respectively. Observations show that: plus an anti-viral mixture for the treatment of epidemic hemorrhagic fever has a significant clinical effect.